We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Group O Found to Be Most Susceptible to Cholera

By LabMedica International staff writers
Posted on 18 Sep 2012
The probability of becoming seriously ill from cholera depends on one’s blood group. More...
Recent research showed that it is possible to find a new treatment for this troublesome illness by studying the molecular structure in the toxin in the cholera bacteria.

Three to five million people are infected by cholera yearly. The mortality rate is high: one hundred thousand people die from the infection every year. “Cholera depends on the blood group. Some blood groups have an increased risk of becoming seriously ill,” said Prof. Ute Krengel, from the department of chemistry at the University of Oslo (Norway).

When cholera bacteria multiply in the body, they create a poison called cholera toxin. The toxin must bind to the cell membrane before it can penetrate further into the intestinal cell and create mayhem. By studying the molecular structure of cholera toxins, researchers can discover how the toxins bind to intestinal cells at the level of the atom. Prof. Krengel’s goal was to find a new drug that prevents the cholera toxin from binding to the intestine and that ensures that the toxin is harmlessly dispersed from the body.

Cholera leads to violent diarrhea. The patient can lose up to 12 L of fluid every 24 hours. The treatment is a saline fluid replacement. “It must be administered as soon as possible and in large quantities. If the patient is unconscious already, the saline solution must be given intravenously. Antibiotics are of no use,” explained Prof. Gunnar Bjune, from the Institute of Health and Society at the University of Oslo.

The cholera bacterium is originally from Bangladesh, but in the past 200 hundred years, it has spread to much of the world and has established a firm foothold in many Asian and African countries. “Patients with blood group O are most at risk of becoming seriously ill. Those with blood groups A, B or AB are more protected against cholera,” said Prof. Krengel.

The Bangladeshi population is evenly distributed between blood groups O, A, and B. In Africa, most people have blood group O. Nearly everyone in the indigenous population in Latin America have group O. When cholera hits these areas, it hits especially hard. In collaboration with the Oslo University Hospital and the Biotechnology Centre, Prof. Krengel’s research group examined whether the probability of becoming seriously ill with cholera depends on blood groups. By studying the molecular structure in the toxin in the cholera bacterium, it is possible to find a new remedy for the dreaded illness, determine how strongly the cholera toxin binds, how long it takes to bind, and how long it stays bound to receptors on the intestinal cells.

The cholera toxin binds to small receptors on the intestinal wall. The receptors consist of small straws with attached sugar molecules. They are to protect the cells against harmful intruders. Unfortunately, the receptors can be exploited. “We want to develop new medicines that bind to the cholera toxin so that it cannot bind to the intestinal cells,” stated Prof. Krengel. The cholera toxin consists of two parts. The researchers study the lower part, which binds to the receptors. “We have discovered that the cholera toxin binds differently than previously thought,” she noted. The investigators will now examine how important the various amino acids are in the binding process and which amino acids bind the most. To penetrate into the intestinal cells, the cholera toxin must first get through mucous layer. “Our results suggest that the cholera toxin uses longer to penetrate the mucous layer if the patients have blood group antibodies in the mucous. Four out of five people have blood group antibodies in the mucous. Those with blood group O are the least protected and therefore get sicker than others.”

In its advanced research, the researcher have created a biologic model of how the cholera toxin enters intestinal cells. They do not use real cholera bacteria. Doing so would be too hazardous. Instead, they use Escherichia coli bacteria, which is the primary model bacterium for cell biologists. “They are easy to make and much quicker and safer to work with. We must grow large quantities in order to study the bindings,” said PhD candidate Julie Heggelund, whose background is in molecular biology.

To create synthetic cholera toxins-or to be precise: to create the lower part of the toxin--the scientists must manipulate the genes in E. coli bacteria. When Prof. Krengel had produced the lower part, she killed the bacteria in a pressure cooker. The receptors are synthetic sugar molecules. Microscopes are of no use in finding the structure of the cholera toxin and receptors: the resolution is not good enough. Researchers must rely on X-rays, which have such a short wavelength that most penetrate empty space in molecules. However, before they can get started with the X-ray machine, the researchers must crystallize the toxin and receptor molecules.

By interpreting the X-rays that are spread by the crystal, researchers can calculate what the structure of the atom looks like. This can be compared to sending laser light through a sieve. Studying the light that is spread by the mesh of the sieve allows researchers to calculate what the sieve looks like.

Each exposure is two-dimensional (2D). To create a three-dimensional image, researchers irradiate the toxin crystal up to 500 times from different angles. Although the imaging only takes a few days, the interpretation of the molecular structure can take several months.

Related Links:

University of Oslo




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
Manual Pipetting Aid
Pipette Controllers macro
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.